Shares of Zydus Lifesciences rose 2 percent in early trade on March 14 after the company launched cancer drug Olaparib, a PARP inhibitor, under the brand name IBYRA in India. At 9:20am ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

The company's India business, comprising both formulations and consumer wellness divisions, contributed 38 per cent of ...

The United States is the company's biggest market accounting for 47 per cent of total revenue, followed by India ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

Zydus Lifesciences Q3 profit rises 30% to Rs 1,023 crore, driven by strong US and domestic market sales. Revenue also ...

The central repository of the drug and medication centre helps to navigate to different sections. Medindia's platform provides carefully curated details on generics, brand names, side-effects ...

Zydus Lifesciences Limited reports 30% profit increase, driven by US formulations business, with strong financial position ...

Zydus Lifesciences Ltd (BOM:532321) reports a robust 17% revenue increase and significant advancements in its innovation pipeline amidst market challenges.